Preclinical News and Research

RSS

FDA meeting confirms Orexo regulatory submission of OX219 NDA on track

A meeting with the US regulatory agency FDA held on July 17 has confirmed that the Swedish pharmaceutical company Orexo is on track with its preparation for a regulatory submission of a new drug approval (NDA) for its medicine for treatment of opioid dependency, OX219.

23 Jul 2012

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).

23 Jul 2012

Researchers identify several gene mutations responsible for medulloblastoma

Researchers at the Stanford University School of Medicine and Lucile Packard Children's Hospital have identified several gene mutations responsible for the most common childhood brain tumor, called medulloblastoma, adding evidence to the theory that the diagnosis is a group of genetically distinct cancers with different prognoses. These and accompanying findings are likely to lead to less-toxic, better-targeted treatment approaches over the next two years, the researchers said.

23 Jul 2012

BioDiem presents positive findings of their eye disease drug at international conference

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.

22 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

The first patient has now been enrolled into the Phase 1 clinical trial sponsored by Viral Genetics' and supported by a donation from Scott and White Foundation. The trial will study Metabolic Disruption Technology (MDT) compounds in combination with an existing cancer therapy to treat drug-resistant ovarian cancer.

20 Jul 2012

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Angion Biomedica initiates BB3 Phase II trial in heart attack

Angion Biomedica Corp. announced today that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction).

19 Jul 2012

Problems walking associated with increased risk of cognitive decline

Problems walking including slow gait and a short stride are associated with an increased risk of cognitive decline, Mayo Clinic researchers have discovered. Their findings are being presented at the Alzheimer's Association International Conference July 14-19 in Vancouver, British Columbia.

19 Jul 2012

BJP publishes data from ESTEVE's E-52862 preclinical studies on pain

ESTEVE announces the recent publication in the British Journal of Pharmacology of important preclinical data that furthers understanding of its highly potent and selective, once-daily, S1R antagonist E-52862, developed by the ESTEVE Research and Development (R&D) team.

18 Jul 2012

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.

17 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

Merck, known as MSD outside the United States and Canada, announced today presentations at the upcoming Alzheimer's Association International Conference (AAIC) being held in Vancouver, British Columbia, Canada on July 14-19, 2012.

16 Jul 2012

WTG to launch ‘Early Drug Development Summit’ in Berlin

With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3rd-4th 2012 in Berlin, Germany.

16 Jul 2012

The Alzheimer's Association recognizes four leading scientists with Lifetime Achievement Award

The Alzheimer's Association recognized four leading scientists for their extraordinary contributions to Alzheimer's disease research at the Alzheimer's Association International Conference (AAIC 2012) in Vancouver, Canada.

16 Jul 2012

James J. Peters Veterans Hospital actively enrolls participants for NIC5-15 phase IIb trial in AD

The James J. Peters Veterans Hospital in Bronx, New York, is actively recruiting participants for a phase IIb clinical trial testing NIC5-15, a disease modifying candidate for Alzheimer's disease.

14 Jul 2012

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today announced that patient dosing has begun in a Phase I clinical trial of OMP-54F28 in patients with advanced solid tumor cancers.

13 Jul 2012

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Spinal Restoration, Inc. announced today the completion of enrollment in the Phase III Investigational New Drug (IND) study of the Biostat System. The Phase III clinical trial is a 260-subject, randomized, blinded, placebo controlled study designed to assess the ability of the Biostat System to reduce pain and improve function in patients with chronic discogenic low back pain.

12 Jul 2012

Arrowhead initiates Adipotide Phase 1 trial in obesity

Arrowhead Research Corporation, a targeted therapeutics company, today announced that the first patient has been dosed in a Phase 1 clinical trial with Adipotide, a new class of treatment for obesity.

11 Jul 2012

PROLOR to present data on long-acting clotting factors for hemophilia at WFH World Congress

PROLOR Biotech, Inc., announced that the company will present data today on its long-acting clotting factors for the treatment of hemophilia at the World Federation of Hemophilia (WFH) World Congress.

11 Jul 2012

Preclinical News and Research

FDA meeting confirms Orexo regulatory submission of OX219 NDA on track

Foundation Fighting Blindness grants US$125,000 to Oxford BioMedica for UshStat Phase I/IIa trial

Researchers identify several gene mutations responsible for medulloblastoma

BioDiem presents positive findings of their eye disease drug at international conference

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Viral Genetics initiates Phase 1 trial of MDT compounds for ovarian cancer

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Angion Biomedica initiates BB3 Phase II trial in heart attack

Problems walking associated with increased risk of cognitive decline

BJP publishes data from ESTEVE's E-52862 preclinical studies on pain

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Ampio announces advancement of NCE001 to preclinical development

Merck to present results from clinical studies on BACE inhibitors at AAIC 2012

WTG to launch ‘Early Drug Development Summit’ in Berlin

The Alzheimer's Association recognizes four leading scientists with Lifetime Achievement Award

James J. Peters Veterans Hospital actively enrolls participants for NIC5-15 phase IIb trial in AD

OncoMed commences dosing in OMP-54F28 Phase I clinical trial for advanced solid tumor cancers

Enrollment complete in Phase III IND study of Spinal Restoration's Biostat System

Arrowhead initiates Adipotide Phase 1 trial in obesity

PROLOR to present data on long-acting clotting factors for hemophilia at WFH World Congress

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics